MALT lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells). The gastrointestinal tract is the most common site of involvement. Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast. Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- MALT lymphoma
- Therapeutic area
- Hematology
- MALT lymphoma
- Extranodal marginal zone B-cell lymphoma
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)
- Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
- Familial primary gastric lymphoma
- Immunocytoma
- lymphoma of mucosa-associated lymphoid tissue
- lymphoma, MALT, somatic
- MALT-lymphoma
- MALToma
- Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
- mucosa-associated lymphatic tissue lymphoma
- mucosa-associated lymphoid tissue lymphoma
- Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
- Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Mucosa-Associated Lymphoid Tissue Lymphoma
- extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
- Severity
- Severe
- Genetic
- Hereditary
Sources for recorded values
- Hematology
- Immunology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0007650
- Parent condition
- MONDO:0003847
Related records
Broader conditions (27)
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Hereditary disease
- Human disease
- Immune system disorder
- Indolent B-cell non-Hodgkin lymphoma
- Leukocyte disorder
- Lymphatic system disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoid system disorder
- Lymphoma
Narrower conditions (5)
- Breast mucosa-associated lymphoid tissue lymphoma
- Gastric mucosa-associated lymphoid tissue lymphoma
- Small intestinal mucosa-associated lymphoid tissue lymphoma
- Thyroid gland mucosa-associated lymphoid tissue lymphoma
- Tonsillar lymphoma
Trials (879)
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
- 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
- 64Cu-LLP2A for Imaging Hematologic Malignancies
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Cohort Study in Newly Diagnosed MZL
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Drugs in development (51)
- Agatolimod sodium Phase 1
- Alvocidib hydrochloride Phase 1
- Amoxicillin Phase 2
- Arsenic Phase 2
- Atezolizumab Phase 2
- Bendamustine Phase 3
- Bismuth subsalicylate Phase 2
- Bortezomib Phase 2
- Bortezomib D-mannitol Phase 2
- Chlorambucil Phase 3
- Cladribine Phase 2
- Clarithromycin Phase 2
- Cyclophosphamide Phase 3
- Dasatinib anhydrous Phase 1
- Doxycycline Phase 2
- Edodekin alfa Phase 2
- Etoposide Phase 2
- Filgrastim Phase 1
- Fludarabine Phase 2
- Fludarabine phosphate Phase 2